63 related articles for article (PubMed ID: 31682844)
1. Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma.
Bresin A; Cristofoletti C; Caprini E; Cantonetti M; Monopoli A; Russo G; Narducci MG
J Invest Dermatol; 2020 May; 140(5):1045-1053.e6. PubMed ID: 31682844
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.
Langdon SP; Kay C; Um IH; Dodds M; Muir M; Sellar G; Kan J; Gourley C; Harrison DJ
Sci Rep; 2019 Dec; 9(1):18742. PubMed ID: 31822716
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic agents for cutaneous T-Cell lymphoma.
Jain S; Zain J; O'Connor O
J Hematol Oncol; 2012 May; 5():24. PubMed ID: 22594538
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of Neosetophomone B inducing apoptosis in cutaneous T cell lymphoma by targeting the FOXM1 signaling pathway.
Kuttikrishnan S; Masoodi T; Ahmad F; Sher G; Prabhu KS; Mateo JM; Buddenkotte J; El-Elimat T; Oberlies NH; Pearce CJ; Bhat AA; Alali FQ; Steinhoff M; Uddin S
J Dermatol Sci; 2023 Nov; 112(2):83-91. PubMed ID: 37865581
[TBL] [Abstract][Full Text] [Related]
5. The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.
Tarantelli C; Gaudio E; Hillmann P; Spriano F; Sartori G; Aresu L; Cascione L; Rageot D; Kwee I; Beaufils F; Zucca E; Stathis A; Wymann MP; Cmiljanovic V; Fabbro D; Bertoni F
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31167506
[TBL] [Abstract][Full Text] [Related]
6. Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphoma.
Sorger H; Dey S; Vieyra-Garcia PA; Pölöske D; Teufelberger AR; de Araujo ED; Sedighi A; Graf R; Spiegl B; Lazzeri I; Braun T; Garces de Los Fayos Alonso I; Schlederer M; Timelthaler G; Kodajova P; Pirker C; Surbek M; Machtinger M; Graier T; Perchthaler I; Pan Y; Fink-Puches R; Cerroni L; Ober J; Otte M; Albrecht JD; Tin G; Abdeldayem A; Manaswiyoungkul P; Olaoye OO; Metzelder ML; Orlova A; Berger W; Wobser M; Nicolay JP; André F; Nguyen VA; Neubauer HA; Fleck R; Merkel O; Herling M; Heitzer E; Gunning PT; Kenner L; Moriggl R; Wolf P
EMBO Mol Med; 2022 Dec; 14(12):e15200. PubMed ID: 36341492
[TBL] [Abstract][Full Text] [Related]
7. Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma.
Au KM; Wang AZ; Park SI
Sci Adv; 2020 Apr; 6(14):eaaz9798. PubMed ID: 32270047
[TBL] [Abstract][Full Text] [Related]
8. Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling.
Zhu DS; Dong JY; Xu YY; Zhang XT; Fu SB; Liu W
Med Sci Monit; 2020 Aug; 26():e927106. PubMed ID: 32804918
[TBL] [Abstract][Full Text] [Related]
9. Cell signaling in cutaneous T-cell lymphoma microenvironment: promising targets for molecular-specific treatment.
Rendón-Serna N; Correa-Londoño LA; Velásquez-Lopera MM; Bermudez-Muñoz M
Int J Dermatol; 2021 Dec; 60(12):1462-1480. PubMed ID: 33835479
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
Wu CH; Yang CY; Wang L; Gao HX; Rakhshandehroo T; Afghani S; Pincus L; Balassanian R; Rubenstein J; Gill R; Bandyopadhyay S; McCormick F; Moasser M; Ai WZ
J Invest Dermatol; 2021 Feb; 141(2):364-373. PubMed ID: 32603749
[TBL] [Abstract][Full Text] [Related]
11. PAK1-Dependent Antitumor Effect of AAC-11‒Derived Peptides on Sézary Syndrome Malignant CD4
Habault J; Thonnart N; Pasquereau-Kotula E; Bagot M; Bensussan A; Villoutreix BO; Marie-Cardine A; Poyet JL
J Invest Dermatol; 2021 Sep; 141(9):2261-2271.e5. PubMed ID: 33745910
[TBL] [Abstract][Full Text] [Related]
12. New nonchemotherapy treatment options for cutaneous T-cell lymphomas.
Xu S; Foss F
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1017-1028. PubMed ID: 33554707
[TBL] [Abstract][Full Text] [Related]
13. "Next top" mouse models advancing CTCL research.
Luo Y; de Gruijl FR; Vermeer MH; Tensen CP
Front Cell Dev Biol; 2024; 12():1372881. PubMed ID: 38665428
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiota analyses of cutaneous T-cell lymphoma patients undergoing narrowband ultraviolet B therapy reveal alterations associated with disease treatment.
Nguyen WQ; Chrisman LP; Enriquez GL; Hooper MJ; Griffin TL; Ahmad M; Rahman S; Green SJ; Seed PC; Guitart J; Burns MB; Zhou XA
Front Immunol; 2023; 14():1280205. PubMed ID: 38274799
[TBL] [Abstract][Full Text] [Related]
15. Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides.
Bordeaux ZA; Reddy SV; Choi J; Braun G; McKeel J; Lu W; Yossef SM; Ma EZ; West CE; Kwatra SG; Kwatra MM
Sci Rep; 2024 Jan; 14(1):1955. PubMed ID: 38263212
[TBL] [Abstract][Full Text] [Related]
16. ATF5 promotes malignant T cell survival through the PI3K/AKT/mTOR pathway in cutaneous T cell lymphoma.
Cao M; Lai P; Liu X; Liu F; Qin Y; Tu P; Wang Y
Front Immunol; 2023; 14():1282996. PubMed ID: 38223508
[TBL] [Abstract][Full Text] [Related]
17. Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment.
Yadav M; Uikey BN; Rathore SS; Gupta P; Kashyap D; Kumar C; Shukla D; Vijayamahantesh ; Chandel AS; Ahirwar B; Singh AK; Suman SS; Priyadarshi A; Amit A
Front Oncol; 2023; 13():1235711. PubMed ID: 37746258
[TBL] [Abstract][Full Text] [Related]
18. Extranodal lymphoma: pathogenesis, diagnosis and treatment.
Yang H; Xun Y; Ke C; Tateishi K; You H
Mol Biomed; 2023 Sep; 4(1):29. PubMed ID: 37718386
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
